Analytical evaluation of the cobas® 6800 system for the detection and quantification of BK Virus (BKV) and Epstein Barr Virus (EBV) at a US solid organ and hematopoietic stem cell transplant center

Elizabeth L Palavecino; Tonika Ridley; Louise Hester; Sara J Blosser

doi:10.1016/j.diagmicrobio.2022.115884

Analytical evaluation of the cobas® 6800 system for the detection and quantification of BK Virus (BKV) and Epstein Barr Virus (EBV) at a US solid organ and hematopoietic stem cell transplant center

Diagn Microbiol Infect Dis. 2023 Mar;105(3):115884. doi: 10.1016/j.diagmicrobio.2022.115884. Epub 2022 Dec 21.

Authors

Elizabeth L Palavecino¹, Tonika Ridley², Louise Hester², Sara J Blosser³

Affiliations

¹ Department of Pathology, Wake Forest School of Medicine, Winston Salem, NC, USA; Department of Pathology, Atrium Health -Wake Forest Baptist, Winston Salem, NC, USA. Electronic address: epalave@wakehealth.edu.
² Department of Pathology, Atrium Health -Wake Forest Baptist, Winston Salem, NC, USA.
³ Medical and Scientific Affairs, Roche Diagnostics Corporation, Indianapolis, IN, USA.

PMID: 36630742
DOI: 10.1016/j.diagmicrobio.2022.115884

Abstract

The cobas® EBV and BKV assays are the first FDA-approved, quantitative assays for monitoring posttransplant reactivation of these viruses. In this study, we assessed performance of the fully-automated cobas® assays, compared with Diasorin Molecular ASR, our laboratory developed test, and demonstrated a strong interassay correlation for BK and EBV monitoring.

Keywords: Diasorin Molecular EBV and BKV ASR; EBV and BKV quantitative assays; The cobas® EBV and BKV assays.

MeSH terms

BK Virus* / genetics
DNA, Viral
Epstein-Barr Virus Infections* / diagnosis
Hematopoietic Stem Cell Transplantation* / adverse effects
Herpesvirus 4, Human / genetics
Humans
Kidney Transplantation*
Polyomavirus Infections* / diagnosis
Viral Load

Substances

DNA, Viral